Mersana Therapeutics (MRSN) Tops Q3 EPS by 1c

Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $9.3 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold